Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.
Diab Vasc Dis Res · 2025
Last updated 2026-05-28In a study of 75 Japanese patients with type 2 diabetes taking oral semaglutide, total calorie intake dropped after 3 months, with the biggest reduction in carbohydrates. Patients also reported less craving for sweets, chocolate, and starchy foods, as well as lower overall food cravings and difficulty resisting them. On average, blood sugar control (HbA1c) and body mass index (BMI) also decreased during the same period.
AI summary of the abstract below.
| Journal | Diab Vasc Dis Res, 2025 |
|---|---|
| Citations | 3 |
| Molecules | semaglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
BACKGROUND: This study aimed to investigate the effects of oral semaglutide on the changes in food preference of Japanese patients with type 2 diabetes.
METHODS: This retrospective multicenter study included 75 patients with type 2 diabetes who received oral semaglutide. The primary outcome was the change in the score of brief-type self-administered diet history questionnaire (BDHQ) score 3 months after the initiation of oral semaglutide treatment. The secondary outcome was the change in the Control of Eating Questionnaire (CoEQ), HbA1c, and body mass index (BMI) after 3 months.
RESULTS: The median age, BMI, and HbA1c of the 23 participants were 64.0 years, 26.9 kg/m, and 7.6% (59 mmol/mol). The BDHQ results showed total energy was significantly reduced. Among the individual nutrients, carbohydrates most decreased. The CoEQ results particularly showed declines in cravings for something sweet, chocolate or chocolate flavored foods, and starchy foods, satisfaction at meals, frequency and intensity of food craving, difficulty of resisting the craving for food, and frequency of eating in response to cravings for food were significantly lower after 3 months. The mean HbA1c and BMI significantly decreased.
CONCLUSIONS: In Japanese patients with type 2 diabetes, oral semaglutide treatment decreased total energy intake and changed food preferences.
Verbatim abstract via PubMed 39878627 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.